Expression of STAT3 in non-small cell lung cancer and its clinical significance

Hongcheng Wang, Xiu Lan, Benyan Song, Caixia Xin, Chao Wang, Hong Dai

Department of Respiratory Medicine, The Affiliated Hospital of Luzhou Medical College, Luzhou, China.
Department of Respiratory Medicine, The Affiliated Hospital of Pan Zhi-Hua Medical College, Panzhihua, China.
Department of Respiratory Medicine, The Center Hospital of Lishui City, Lishui, China.

DOI: 10.4236/alc.2013.22005                

Abstract

Signal transducer and activator of transcription 3(STAT3) plays an important role in tumor occurrence and development. Here we attempt to evaluate the clinical diagnostic value of STAT3 as a potential tumor marker by detecting the expression of STAT3 in blood of non-small cell lung cancer (NSCLC) patients. Immunohistochemistry was applied to detect STAT3 protein in A549 cells and MRC-5 cell, real time PCR was applied to detect STAT3 mRNA and ELISA was applied to detect the expression of STAT3 protein in NSCLC patients, benign lung disease group and healthy controls. The expression levels of STAT3 mRNA and STAT3 protein in A549 cells and NSCLC patients were significantly higher (P < 0.01). The areas under ROC curves (Az) of STAT3 mRNA and STAT3 protein were 0.870 and 0.860 respectively, which had no significant difference (P > 0.05). When comparing the Az of STAT3 protein with CEA, CA125 and CYFRA21-1 respectively, there was no significant difference (P > 0.05). And we compared the Az of the four joint detection (STAT3 + CEA + CA125 + CYFRA21-1) with the three joint detection (CEA + CA125 + CYFRA21-1), 0.930 and 0.841, respectively, P < 0.05. It appears that the diagnostic value and accuracy of STAT3 is equivalent with CEA, CA125, and CYFRA21-1 in NSCLC, and to joint with other three can achieve higher diagnosis value.

Keywords

Signal Transducer and Activator of Transcription 3; Non-Small Cell Lung Cancer; Tumor Marker; ROC Curve; Diagnostic Value

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Stieber, P., Hasholzner, U., BodenmuJller, H., et al. (1993) CYFRA21-1. A newmarker in lung cancer. Cancer, 72, 707-713. doi:10.1002/1097-0142(19930801)72:3<707::AID-CNCR2820720313>3.0. CO;2-X
[2]	Henderson, R.A. and Finn, O.J. (1996) Human tumor antigens are ready to fly. Advances in Immunology, 62, 217-256. doi:10.1016/S0065-2776(08)60431-9
[3]	Zhao, X., Wu, X.D., Xu, W.J., et al. (2011) Diagnostic value of combined detection of NSE, CYFRA2I-1, CEA and CA125 in lung carcinoma. Journal of Radioimmunology, 24, 696-697
[4]	Niho, S. and Shinkai, T. (2001) Tumor markers in lung cancer. Japanese Journal of Cancer and Chemotherapy, 28, 2089-2093.
[5]	Campbell, C.L., Jiang, Z., Savarese, D.M., et al. (2001) Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. American Journal of Pathology, 158, 25-32. doi:10.1016/S0002-9440(10)63940-5
[6]	Liu, J. and Kern, J.A. (2002) Neuregulain-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. American Journal of Respiratory Cell and Molecular Biology, 27, 306-313. doi:10.1165/rcmb.4850
[7]	Wang, F.-Y., Zhang, Y.-Q., Luo, M., et al. (2011) The expressions of p-Stat3, VEGF-C and MMP-2 in nonsmall cell lung cancer and their relationship with lymph node metastasis. Carcinogenesis, Teratogenesis & Mutagenesis, 23, 107-122.